Prerpints.org logo
Preprint
Review

Early Onset Gastrointestinal Malignancies: An Investigation into a Rising Concern

Altmetrics

Downloads

124

Views

40

Comments

0

A peer-reviewed article of this preprint also exists.

Submitted:

12 March 2024

Posted:

12 March 2024

You are already at the latest version

Alerts
Abstract
This is growing recognition of early onset gastrointestinal (GI) malignancies in young adults
Keywords: 
Subject: Medicine and Pharmacology  -   Gastroenterology and Hepatology

1. Introduction

The definition of a young adult, typically used to assess cancer incidence, encompasses individuals below 50 years of age [1]. There has been a rise in the incidence of malignancies among young adults reported internationally – most frequently gastrointestinal cancers, breast cancer, endometrial cancer, kidney cancer, bone marrow cancer, head and neck cancers, as well as prostate cancer [1]. Herein, we will describe the increase in reported early-onset gastrointestinal malignancies, which include esophageal, gastric, colorectal, liver, pancreatic, and biliary tract (Table 1) [2,3].

2. Esophageal Cancer

2.1. Esophageal Cancer: Introduction

According to a GLOBCAN database analysis, there were more than 604,000 new cases of esophageal cancer and approximately 544,000 deaths attributed to this disease in the year 2020, making it the eighth most common cancer worldwide [4]. Incidence and mortality rates were the highest in Eastern Asia and Southern and Eastern Africa, and the malignancy is 2-3 fold higher in men than women [4].

2.2. Global and US Incidence of Esophageal Cancer (EAC and SCC)

Squamous cell carcinoma (SCC) and esophageal adenocarcinoma (EAC) are the two primary types of esophageal malignancies, each associated with distinct risk profiles. Historically, SCC has been the most common type of esophageal cancer worldwide; however, over the past three decades, there has been a significant increase in the incidence of EAC, making it the predominant form of esophageal malignancy in Westernized countries [4]. While SCC originates from the stratified squamous epithelial lining of the esophagus, EAC develops in the columnar glandular cells that replace the squamous epithelium (from the precursor Barrett’s esophagus). Barrett’s esophagus (BE) is characterized by distinct and identifiable metaplastic salmon-colored “tongues’’ that extend from the gastroesophageal junction.
Demographically, SCC and EAC exhibit substantial differences and nuances. These variations in demographic patterns emphasize the distinct characteristics and complexities associated with each type of esophageal cancer. In the United States (US) the incidence of SCC is notably higher in the Black population compared to the White population. Remarkably, the incidence of SCC has decreased across all racial and ethnic groups, with a particularly higher rate of decrease observed in the Black population [5]. EAC exhibits a higher incidence in the White population than in the Black population. The racial differences in the incidence of EAC are partly attributable to the increased risk of BE in the White population. The prevalence of BE is higher in men compared to women (2:1 ratio), thus the progression to EAC is also greater in men [6].

2.3. Incidence of Esophageal Cancer in Young Adults

In an analysis of the US Surveillance, Epidemiology, and End Results (SEER) database, the annual incidence of EAC in individuals under 50 years of age increased more than three-fold from 0.08 per 100,000 to 0.27 per 100,000 between 1975 and 2015 [7]. In another analysis from Australia the cohort of young-onset individuals exhibited a substantial upward trend in the incidence rates of EAC. The incidence rate ratio (IRR) for the period 2010-2017 compared to 1990-1999 was 2.60 (95% CI 1.35-5.03) [8].
An analysis of the National Cancer Database revealed a plateau or slight decline in total EAC rates from 2004 to 2015; early onset EAC incidence in the period of 2004-2006 was notably 4.2% higher than that observed in 2013-2015 [9]. A recent SEER analysis revealed a stabilization or decline in overall incidence rates of EAC; for the 50-54 year old cohort, the annual percent change (APC) in EAC rates from 2000 to 2019 was (-)1.15. In the 45-49 year old cohort, from 1992 to 2019 (including an initial increase from 1992 to 2000), the APC was (-) 0.13. These figures indicate that there has been a stabilization or potential decrease in rates of EAC within the 49-54 year-old age group up until 2019 [10]. A broader analysis of the SEER database, covering a wider variety of age groups starting at 20 years of age and including all histologic types of esophageal malignancies, also observed a decline in esophageal cancer rates for the 18-49 year-old age cohort from 2004 to 2013. The study reported an average annual percent change of (-)1.8% in incidence rates during this period [11].
Esophageal cancer, encompassing both SCC and EAC, carries a grim prognosis and outcome for the majority of its cases, as the overall five-year survival rate is 15% to 20% [12]. Patients typically have advanced disease at the time of diagnosis which contributes to the lower survival rate. However, there has been a recent increase in 1-year survival for EAC and SCC in high-income countries due to advances in treatment [13].

2.4. Risk Factors for Early-Onset Esophageal Cancer

SCC and EAC both have distinct risk profiles; therefore, each histologic type of EC was observed to have different genetic and environmental factors.

2.4.1. Squamous Cell Carcinoma Risk Factors

There is a paucity of research investigating early onset SCC. A recent study from Tanzania identified multiple exposures as risk factors for early-onset esophageal SCC, including infrequent teeth cleaning, exposure to secondhand tobacco smoke, and pest infestation of grain and/or nuts [14]. Lower socioeconomic status, a family history of SCC, tobacco smoking, home-brewed alcohol consumption, home storage of grain and/or nuts, and use of firewood for cooking were associated with SCC risk in the older age group but not in the younger population. Hot beverage intake was found to be associated with an increased risk of SCC regardless of age.

2.4.2. Esophageal Adenocarcinoma Risk Factors

One California study found a 56% increase of early-onset EAC in obese patients and a striking 166% increase in morbidly obese patients [15]. Another US study with 335 EAC patients confirmed the relationship between obesity and early-onset EAC [16]. Other known risk factors such as sex, gastric acid reflux symptoms, and smoking did not show significant differences between early and late-onset patients [16]. In a study from Netherlands, heredity was implicated in some cases of early-onset EAC, with Familial BE accounting for 7% of cases. TP53 and P16 mutations were common in both early-onset and conventional EACs, but additional mutations in different genes were found exclusively in early-onset cases [17].

2.5. Improvements in Detection Measures and Screening Guidelines for Esophageal Cancer

Guidelines recommend a single screening endoscopy for patients with chronic reflux symptoms and three or more additional risk factors for BE. These risk factors include male sex, age >50 years, white race, tobacco smoking, obesity, and a family history of BE or EAC in a first-degree relative [18]. If the screening esophagogastroduodenoscopy (EGD) reveals non-dysplastic BE, surveillance every 3-5 years is recommended. However, if low-grade dysplasia is detected, then annual endoscopy is recommended until two consecutive endoscopies show no evidence of dysplasia [18].
Advancements in screening for SCC are limited due to the complexity of the disease’s precursors. Even in countries like China where SCC is highly prevalent, population-based screening is not currently recommended, as no screening test has been proven to lower mortality in average-risk individuals. Further studies are necessary to assess the cost-effectiveness and feasibility of screening for SCC [19].
While EGD is the primary method for detecting BE and SCC, there are viable and cost-effective alternatives available. Unsedated transnasal endoscopy (uTNE) involves using an ultra-thin endoscope introduced through the nasal cavity to examine the esophagus and stomach. uTNE has demonstrated similar sensitivity and specificity for detecting BE as EGD, and comes with the advantage of lower cost due to the lack of sedation and need for intensive monitoring [20]. Another cost-effective alternative is the cytosponge, which consists of a gelatin-coated sponge attached to a string, and is swallowed by the patient. The cytosponge expands within the esophagus to collect cytology specimens and has comparable sensitivity and specificity of BE detection to EGD (73% and 94%, respectively). With the emergence of genomic or molecular markers for BE and EAC, there is a possibility that cytosponge will be incorporated into the previously discussed surveillance protocols for BE [21]. Additionally, a U.K. study indicated that the cytosponge was more comfortable, practical, and economical than endoscopy [22].

3. Gastric Cancer

3.1. Gastric Cancer: Introduction

In 2020, gastric cancer was ranked as the fifth most common malignancy in the world and the second most lethal, with men experiencing a two-fold greater incidence rate [23,24]. The incidence of gastric cancer was found to be the greatest in Asia, followed by the Caribbean, Europe, and Oceania. The lowest incidence occurred in North America and Africa. Hispanic and Black patients are disproportionately affected by early-onset gastric cancer and are often faced with a worse prognosis. This disparity could be related to delays in diagnosis and a reduced access to optimal care [9]. A 2008-2014 retrospective cohort study confirmed that lower socioeconomic status and racial and ethnic minorities face a higher gastric cancer risk than non-Hispanic whites [23].
Approximately 95% of all gastric malignancies are adenocarcinomas, and the remaining 5% of cases mainly comprise gastrointestinal stromal tumors, neuroendocrine tumors, and lymphomas. Gastric adenocarcinomas are commonly categorized anatomically as either gastric cardia or non-cardia cancer. These classifications have distinct epidemiological features; for instance, non-cardia gastric cancer is more common in East Asian and Latin American countries, while gastric cardia cancer is more common in Western Europe and North America [25].
Recent findings also predict an overall increase in both the annual incidence and mortality rates of gastric cancer by the year 2040 to an estimated 1.8 million new cases and 1.3 million deaths, with gastric cancer increasingly found in the young [26]. One study estimates 30% of newly diagnosed gastric cancers are early onset [27]. Another international population-based cohort analyzing data from 1980 to 2018 found the incidence of gastric cancer to decrease in most regions amongst older adults but increase in those under the age of 40. [28]. These findings of increased early-onset gastric cancer incidence are confirmed by a Chinese study that analyzed trends from 1990 to 2019 [29].

3.2. Risk Factors of Early-Onset Gastric Cancer

Recent research suggest a large genetic component to early-onset gastric carcinogenesis [30,31]. Approximately 10% of those diagnosed with early-onset gastric cancer have a family history of the disease [13]. CDH1 germline mutations can lead to abnormal encoding of the E-cadherin protein, which may result in hereditary diffuse gastric cancer associated with worse overall survival [32,33,34]. Genetic mutations such as the CDH1 germline mutation or hMLH1 germline mutations make up 2–3% of early-onset gastric cancer cases in North America [35]. A study evaluating the risk of developing gastric cancer in patients with Lynch syndrome found that the cumulative lifetime risk ranges from 3% to 39% across all mutations (MLH1, MSH2, MSH6, PMS2, and EPCAM) [36]. Peutz-Jeghers syndrome (PJS) is another hereditary risk factor for early-onset gastric cancer [37]. Additionally, one Japanese study evaluating the risk of malignant tumors as a result of juvenile polyposis syndrome (JPS) found that in a sample of 171 cases, the lifetime risk of gastric cancer was as high as 73.0% [38].
The remaining 90% of those diagnosed with early-onset gastric cancer who lack family history of the disease may have environmental triggers, such as H. Pylori, especially seen with the cagA strain contributing to non-cardia cancers [39,40,41]. Atrophic gastritis occurring from H. Pylori can also predispose to early onset gastric cancer [42,43,44]. Two recent studies found a strong positive association between obesity and early-onset gastric cancer [45] [15]. A BRFSS (Behavioral Risk Factor Surveillance Survey) analysis done to explore the difference in rates of potential risk in both early-onset gastric cancer and traditional gastric cancer found a strong positive association between heavy drinking and the risk of both early-onset gastric cancer and traditional gastric cancer, though smoking did not show any risk association [46].

3.3. Screening for Gastric Cancer, Current Detection Measures

Currently, there are no guidelines recommending routine screening for gastric cancer in the United States, though recent research recommends consideration of EGD screening for high risk populations with a family history or genetic predisposition for gastric cancer [47,48]. The American College of Gastroenterology (ACG) has outlined screening recommendations for those with hereditary gastric cancer syndromes. The ACG recommends individuals with or at risk for Lynch Syndrome to screen for Gastric Cancer by EGD with gastric biopsy beginning at ages 30-35, patients with symptoms or family history of PJS to undergo genetic evaluation, and individuals with symptoms of PJS to also undergo a genetic evaluation [49]. The implementation of screening via EGD in East Asian countries such as Japan and Korea has proven effective in reducing gastric cancer-related mortality while also being cost-efficient for those regions, based off their local incidence rates. Japanese guidelines recommend screening every 2-3 years for individuals above the age of 50. Koreans above the age of 40 are recommended for screening every 2 years [48,50,51,52].

4. Liver and Biliary Tract Malignancies

4.1. Liver and Biliary Tract Malignancies: Introduction

Primary liver cancer encompasses hepatocellular carcinoma (HCC), which accounts for 75% to 85% of cases, and intrahepatic cholangiocarcinoma (ICC), constituting 10% to 15% of cases, alongside other infrequent and rare types. The main risk factor for HCC is the chronic hepatitis B virus (HBV) that confers a near 100-fold risk to chronic carriers [53]. ICC is a malignancy involving the lining of the bile ducts, sometimes also showing perineural and lymphovascular invasion.
According to a GLOBOCAN study in 2020, primary liver cancer ranks as the sixth most commonly diagnosed cancer and the third leading cause of cancer-related deaths worldwide, accounting for approximately 906,000 new cases and 830,000 deaths [24]. A meta-analysis, encompassing a pooled analysis of annual percent change for HCC and ICC incidence rates between 2008 and 2019, yielded values of +2.6 and +4.3, respectively. Subgroup analyses illuminated increasing trends in primary liver cancer cases within the North America/Europe/Australia region (which was previously considered as regions of relatively low incidence), while contrasting trends of decrease and stability were noted in Asia (traditionally considered a high-incidence region) [54]. Furthermore, the rates of both incidence and mortality exhibited a consistent pattern of being 2 to 3 times higher in men compared to women across most regions [24].
In a study of SEER data, primary liver cancer incidence and death rates were notably elevated among American Indian/Alaska Natives, with figures reaching 15.2 and 11.9 per 100,000, respectively. These rates were more than double those recorded for non-Hispanic white patients, which stood at 6.3 and 5.5 per 100,000, respectively. Black, Asian American/Pacific Islander and Hispanic patients exhibited higher incidence and mortality rates in comparison to White patients. Increasing trends in incidence over time were observed for all of these racial groups except for American Indian/Alaska Natives and Asian American/Pacific Islanders [55].
A study conducted in the United States revealed that the incidence of HCC was highest among Asian American/Pacific Islanders, with Black, Hispanic, and non-Hispanic white patients. following in descending order. However, the same study identified a noteworthy trend in HCC incidence, with Hispanics experiencing the highest percentage increase, while Asians saw a decline in incidence [56].
In another United States study focused on ICC, it was observed that the Asian American/Pacific Islander population had the highest incidence rates at 1.5 per 100,000, followed by Hispanic at 1.18 per 100,000, American Indian/Alaska Native at 0.88 per 100,000, White at 0.88 per 100,000, and Black at 0.77 per 100,000 [57].

4.2. Liver and Biliary Tract Malignancies: Incidence Trends in Young Adults

A SEER analysis revealed that the incidence of HCC was decreasing in the younger and middle-aged (<60 years) adults in the US, irrespective of sex, race, or ethnicity. Specifically, the incidence for the 40-49 cohort exhibited a substantial decrease (APC: -12.2%) from 2009 to 2015 [58]. Another more recent (2010 to 2019) SEER analysis also observed a decrease (APC: -4.67%, 95% CI -5.7, -3.6) in HCC rates among young adults [3].
Trends in ICC incidence are opposite to those of HCC. A U.S. population study found that ICC incidence rates increased among the 18-44 age cohort, with an estimated APC of +3.3% from 1999 to 2013[59]. A SEER analysis, conducted from 2010 to 2019 recorded an APC of +8.12% for early-onset ICC, indicating one of the fastest-growing incidence rates among gastrointestinal cancers in early-onset individuals [3].

4.3. Liver and Biliary Tract Malignancies: Risk Factors of HCC and ICC

There is limited understanding of genetic risk factors for HCC in young adults. A family history of HCC is associated with increased risk of early onset HCC and this increase is greater in HBV carriers [60,61]. The other roughly 90% of early-onset HCC is attributed to environmental factors, including chronic infection with HBV. Smoking has been proven to be associated with early- but not late-onset HCC, and cirrhosis has been identified to have a lower incidence among early-onset patients than late onset [62,63]. Metabolic dysfunction-associated fatty liver disease associated with obesity may contribute to early-onset HCC [1].
There is also a dearth of research involving genetics and family history leading to early onset ICC. Caroli’s disease – characterized by cystic dilations of the intrahepatic bile ducts – is inherited in an autosomal recessive manner, with ICC occurring in up to 7% of affected individuals [64]. Other established risk factors for ICC include parasitic infections, hepatolithiasis, and primary sclerosing cholangitis (PSC) [65]. In Western populations, especially among younger individuals, the largest risk factor for ICC – primary PSC – is linked to a substantial 400-fold elevation in the risk of developing ICC [66]. The recent increase in PSC incidence amongst Westerners may offer an explanation for the recent increase in ICC amongst younger adults [67].

4.4. Liver and Biliary Tract Malignancies: Current Detection Measures and Screening Guidelines

The American Association for the Study of Liver Diseases (AASLD) recommends HCC screening for all adults with liver cirrhosis to decrease mortality. The AASLD advises liver ultrasound (US) every 6 months for HCC screening with additional testing of serum alpha-fetoprotein (AFP). CT or MRI are not recommended for HCC surveillance in individuals with cirrhosis due to a lack of data on efficacy and cost-effectiveness of these modalities [68,69].
There are no current guidelines recommending routine ICC screening. However, a study performed at Mayo Clinic demonstrated that annual screening with serum CA 19-9 and cross-sectional abdominal imaging for PSC patients helped identify cancer which may help improve survival through earlier disease discovery [70]. In high prevalence areas of liver fluke infection such as Thailand, one recent study demonstrated that screening ultrasound led to the diagnosis of ICC at an earlier stage [71,72].

5. Pancreatic Cancer

5.1. Pancreatic Cancer: Introduction

Pancreatic ductal adenocarcinoma (PDAC) is the most common form of pancreatic cancer and accounts for more than 90% of all cases [73]. PDAC typically arises from pancreatic ductal cells, often originating from pancreatic intraepithelial neoplasia (PanIN), and less frequently from intraductal papillary mucinous neoplasms (IPMNs) [74].
According to GLOBOCAN, in 2020, there were 496,000 new cases of PDAC, almost matched by the number of deaths (466,000), positioning it as the seventh leading cause of cancer-related death [24]. Globally, both incidence and mortality rates have witnessed a 55% and 53% increase, respectively, from 1992 to 2017, and have risen across all age groups [75]. The highest incidence rates were documented in North America, Europe, and Australia [76]. Incidence rates are higher in men compared to women, with a reported global incidence of 5.7 per 100,000 for men and 4.1 per 100,000 for women [24,77]. It is estimated that PDAC will be the second leading cause of malignancy-related mortality in the US by 2030 [78,79].
United States data from 2001 to 2015 indicate a higher incidence of PDAC among the Black population across every age group in comparison to the white population [80]. The overall incidence rates were 19.4 per 100,000 for whites and 24.7 per 100,000 for Blacks. A similar pattern was noted in mortality rates [80]. Among White patients, incidence increased across all age groups from 2001 to 2015, with the most significant increases observed in the younger age groups (<50 years). Among Black patients, there were noteworthy incidence increases in most age groups except for those aged 40-49 and those over 80 years [80].

5.2. Pancreatic Cancer: Incidence in Young Adults

Early-onset pancreatic cancer (EOPC) remains relatively uncommon, but recent research indicates a rise in incidence. An analysis of the SEER database from 1995 to 2014 revealed that the average APC in pancreatic cancer incidence in the 45 to 49 age group was +0.77%(95% CI, 0.57–0.98), and was +4.34% (95% CI, 3.19–5.50) in the 25 to 29-year-old age group [81]. A similar APC (+3.4%) in incidence for very early onset (20-39 years at diagnosis) was seen in a separate analysis from 2000-2019 [82].
Another analysis of the SEER from 2004 to 2016 demonstrated a consistent rise in annual age-adjusted incidence rates (AAIR) of EOPC across all sexes and racial groups. Additionally, while the AAIR was higher in men, the rate of increase was more rapid among women. Among racial groups, African Americans exhibited the highest AAIR, followed by non-Hispanic whites, and Hispanic patients displayed the lowest AAIR, albeit with the fastest increase. The analysis further unveiled that the incidence of all stages of the disease is on the rise, suggesting that the escalation in incidence rates may not primarily stem from the detection of early-stage cases [83].
The prognosis for PDAC is grim, having one of the lowest 5-year relative survival rates among all cancer types. There has been modest improvement in 5-year relative survival rates, increasing from 9% in 2011 to 13% in 2024 [84,85]. However, the overall PDAC outcomes remain poor [84]. Additionally, an analysis of the SEER database from 2004 to 2018 found that EOPC was linked to a higher 5-year overall survival (6.9% vs 5.5%) compared to late-onset PC [86].

5.3. Pancreatic Cancer: Risk Factors

A high incidence of PDAC is observed in hereditary syndromes, including familial atypical multiple mole melanoma syndrome (FAMM), Lynch syndrome (hereditary nonpolyposis colorectal carcinoma), Peutz–Jeghers syndrome (PJS), hereditary breast and ovarian cancer syndrome (HBOC), familial adenomatous polyposis (FAP), and hereditary pancreatitis. Moreover, familial PDAC is regarded as a distinct clinical entity that is independent of other known familial syndromes, in which individuals have a significant family history of PDAC typically involving two or more first-degree relatives [87].
Approximately 5-10% of EOPC cases are associated with familial PDAC. A US study involving 826 patients reported that the mean age of diagnosis amongst familial PDAC patients was 57.6 years, decreased as compared to the sporadic group’s mean age of 61 years. Notably, the familial group exhibited a significantly higher proportion of patients diagnosed at age < 50 years than the sporadic group (36.7% vs. 18.3%; p = 0.017) [88]. A more recent study confirmed that a family history of PDAC in a first-degree relative correlated with an increased risk of both EOPC (OR 2.53, 95% CI 1.77-3.61) and very early-onset PDAC (VEOPC), showing a similar risk elevation in both categories [89]. Research indicates that EOPC patients have a notably higher prevalence of germline mutations, including ATM, APC, BRCA1, BRCA2, CDKN2A, MLH1, MSH2, MSH6, PMS2, PALB2, STK11, and PRSS1, with BRCA1 and BRCA2 mutations being the most common for early onset cases [90].
Other contributors to EOPC include environmental factors. A comprehensive case-control analysis using age below 60 years classified as EOPC (n=1954) and under 45 years as VEOPC (n=226) revealed that consuming ≥ 26 g of alcohol per day (equivalent to two or more standard drinks) was linked to an overall elevated risk (OR 1.49, 95% CI 1.21-1.84). This association was more pronounced in the VEOPC group (<45 years) with an odds ratio of 2.18 (95% CI 1.17-4.09), although the interaction between alcohol and age did not reach statistical significance (p=0.20) [89]. Diabetes mellitus was associated with a higher risk of EOPC (OR 1.55, 95% CI 1.16-2.06) but not VEOPC (OR 0.85, 95% CI 0.25-2.93). Cigarette smoking demonstrated an elevated risk for PDAC across all age brackets, with an amplified risk for EOPC. However, unlike alcohol, there was no indication of an amplified effect in VEOPC. Obesity, as reflected by a BMI ≥30, was associated with an increased risk of EOPC (OR 1.28, 95% CI 1.08-1.52) but not in VEOPC (OR 1.13, 95% 0.67-1.90) [89]. When comparing risk factors between EOPC and late-onset patients, another study revealed similar findings. There were no differences in terms of sex distribution, medical conditions, and alcohol intake. However, EOPC patients exhibited a higher prevalence of current smokers (56% vs. 28%, p = 0.001) and initiated smoking at a significantly younger average age (19.8 years, 95% CI 16.7–22.9) compared to older patients (26.1 years, 95% CI 24.2–28) (p = 0.001). Current smoking (OR 7.5; 95% CI 1.8–30; p = 0.004) and age at smoking initiation (OR 0.8 for each increasing year; 95% CI 0.7–0.9; p = 0.01) emerged as significant and independent risk factors for the diagnosis of EOPC [91].

5.4. Pancreatic Cancer: Screening Guidelines and Detection

In the screening process for pancreatic cancer, primary imaging tests include endoscopic ultrasonography (EUS), magnetic resonance imaging with magnetic resonance cholangiopancreatography (MRI/MRCP), and computed tomography (CT) with specialized pancreatic protocols. While PDAC screening is not recommended for average risk patients, screening a consideration for high risk populations and associated with early detection. [92].
The International Cancer of the Pancreatic Screening (CAPS) consortium represents the only international effort to provide screening guidelines for individuals at risk of pancreatic cancer based on genetic mutation status and family history. Screening is recommended for patients with carriers of STK11 or CDKN2A mutations, as well as those with a family history and germline BRCA2, BRCA1, PALB2, ATM, MLH1, MSH2, or MSH6 gene mutations. Lastly, individuals from familial pancreatic cancer kindreds are also included if they have at least 2 affected genetically related relatives. The initiation age of surveillance varies is influenced by the specific genetic mutation and family history. For familial pancreatic without known mutations, screening starts at age 50, or 10 years younger than the age of cancer diagnosis for the youngest affected relative. Mutation carriers have tailored starting ages (e.g., PJS at age 40, CDKN2A at age 40, BRCA2, ATM, PALB2, BRCA1, MLH1/MSH2, MSH6 at age 45 or 50). The National Comprehensive Cancer Network (NCCN) guidelines slightly differ from these in that they recommend PJS carriers to begin screening at ages 30-35, and BRCA2, ATM, PALB2, BRCA1, MLH1/MSH2, MSH6 mutation carriers at age 50[93]. These efforts prioritize early detection and aim to improve outcomes by identifying pancreatic cancer at its earliest stages. Additionally, the guidelines emphasize the importance of further research, which includes the identification of models for addressing other established risk factors such as diabetes and markers of metabolic syndrome, smoking habits, family history of other cancers, gene variants revealed through genome-wide meta-analysis, and predictive biomarkers [92,93]

6. Colorectal Cancer

6.1. Colorectal Cancer: Introduction

Colorectal cancer (CRC) is the third most common cause of cancer-related death and the third most frequently diagnosed cancer in the US. Over 90% of cases are adenocarcinomas, and the remaining 10% include neuroendocrine, squamous cell, adenosquamous, spindle cell, and undifferentiated carcinomas [94]. Data from the SEER program and the Centers for Disease Control (CDC) National Program of Cancer Registries revealed that the US incidence of CRC was 33% higher in men than in women from 2015 to 2019 [95]. The global burden of CRC is estimated to reach over 3.2 million new cases and 1.6 million deaths by the year 2040. An analysis of the GLOBOCAN database in the year 2020 demonstrated that the CRC incidence was highest in Australia/New Zealand and European regions, and lowest in several African regions and Southern Asia. Similar results were shown for mortality rates, found to be highest in Eastern Europe and the lowest in Southern Asia [96].
The 5-year survival rate for colorectal cancer has improved in recent years. Previously 50% in the 1970s, 5-year CRC survival is now 65% in one study analyzing data from 2012-2018. This decreased mortality can be attributed to enhancements in screening, imaging, therapy, and surgical technique [95]. However, improvements in CRC screening uptake have not been even across racial and ethnic groups [97]. Black patients still have higher rates of colorectal cancer mortality within the US [98]. For metastatic CRC, non-Hispanic whites saw an increase in 5-year survival rates from 9.8% to 15.7% when comparing 1992-1997 to 2004-2009. However, for these same time periods, Black patients saw an increase in 5-year survival from 8.6% to 9.8%. Hence, Black patients may not be benefiting from advances in screening and treatment [99].

6.2. Colorectal Cancer: Incidence in Young Adults

One study from the German Center for Cancer Registry Data found EO-CRC to constitute over 5% of all CRC cases, and steadily increasing over time [100]. Another American study analyzing SEER data from 1975 to 2003 found similar results, with an increase in EO-CRC incidence in younger populations. With current trends, the incidence of colon and rectal cancers may increase by 90.0% and 124.2%, respectively, for individuals in the 20–34 year age group [101]. Similar trends of an increase in EO-CRC incidence have also been noted in many other countries including Australia, Canada, Denmark, Korea, New Zealand, Slovenia, Sweden, and the UK [102,103,104].

6.3. Risk Factors/Etiologies of Early-Onset Colorectal Cancer

Lower dietary fiber intake, heavy alcohol use, greater read meat consumption, lack of regular NSAID use, and lower educational level are all non-genetic risk factors for EO-CRC. Several risk factors for CRC at an older age – but not necessarily EO-CRC – included smoking, an increased BMI, and lack of aspirin use [105]. One population-based case–control study conducted in Ontario, Canada from 2018–2019 found that a higher consumption of sugary beverages, a history of CRC in a first or second degree family member, and an increasingly Westernized diet increased the risk of EO-CRC. On the contrary, greater calcium supplement use and a previous diagnosis of allergies or asthma were found less likely to be associated with EO-CRC [106].
Around 15-20% of patients with CRC found before the age of 50 have a germline mutation that is linked to the malignancy [107,108]. Germline variants with high penetrance are detected in up to 1 in 10 cases of CRC. [109] Hereditary CRC syndromes include familial adenomatous polyposis syndrome (FAP), Lynch syndrome, and hamartomatous polyposis syndromes. FAP is associated with the APC gene mutation (autosomal dominant inheritance) and MUTYH (autosomal recessive inheritance). Lynch syndrome is associated with abnormalities in the MLH1, MSH2, MSH6, and PMS2 genes. Hereditary hamartomatous syndromes include Peutz-Jeghers syndrome (PJS, with mutations in LKB1/STK11), PTEN-hamartoma tumor syndrome (PHTS, with mutations in PTEN), and juvenile polyposis syndrome (JPS, with mutations in BMPR1A or SMAD4) [110]. Lynch syndrome is the most common hereditary form of CRC, and is implicated in almost 20% of people diagnosed with EO-CRC. In one study, 26% of EO-CRC patients had a first-degree family member also previously diagnosed with CRC. Hence, genetic testing is highly recommended in all patients found to have EO-CRC [108].

6.4. Screening for Colorectal Cancer/Current Detection Measures

Common methods for non-invasive colon cancer detection include guaiac fecal occult blood testing (gFOB), fecal immunochemical testing (FIT), and multitarget stool DNA testing (MT-sDNA, marketed as Cologard). While MT-sDNA has a higher sensitivity than FIT and gFOB, it has up to 3 times more false positive results than FIT [111,112,113]. A randomized population-based study concluded that FIT screening had superior participation and detection rates and should be preferred over gFOB screening if MT-sDNA testing is unavailable [111,114]. The gold standard of CRC screening is colonoscopy. A study involving 88,902 participants over 22 years found that negative colonoscopy is strongly associated with a significantly reduced risk of proximal and distal CRC [115]. Colonoscopy is also used to diagnose CRC or to find and remove colorectal polyps following a positive non-invasive test [111,112]. Another direct visualization test includes flexible sigmoidoscopy; however, it does not include visualization of the entire colon and could lead to missed lesions. CT colonography uses serial radiographic images to visualize the entire colon. Notably, abnormalities noted on flexible sigmoidoscopy or CT colonography typically require a full colonoscopy for a more detailed examination [116]. A blood-based CRC screening test was recently FDA approved (PCR-based Epi proColon) which is intended for use by individuals unable or unwilling to complete other screening modalities. This blood test detects methylated DNA from CRC cells but is only 68.2% sensitive for cancer discovery compared to colonoscopy [117].
The incidence of colorectal adenocarcinoma has been rising in recent years, with 15% more cases diagnosed amongst individuals between the ages of 40 to 49 years from 2014-2016 compared to 2000-2002. Therefore, the United States Preventative Service Task Force (USPSTF) currently recommends screening for colorectal cancer in all individuals starting at 45 years of age, a change from its prior recommendation of starting at age 50. Appropriate intervals and modalities include a colonoscopy every 10 years, flexible sigmoidoscopy every 10 years combined with FIT every year, flexible sigmoidoscopy every 5 years, CT colonography every 5 years, MT-sDNA every 1 to 3 years, or a high-sensitivity gFOB or FIT.
There are variations in CRC screening internationally. For example, the Canadian Task Force on Preventative Health Care does not encourage the use of colonoscopy for CRC screening purposes in healthy individuals without a family history of CRC, though this is a weak recommendation based off low quality evidence. Instead, they recommend Canadians receive gFOBT or FIT in two-year intervals or a flexible sigmoidoscopy every 10 years. Notably, these guidelines cannot be applied to individuals with a history of polyps [118]. Australian national guidelines recommend those without a family history of CRC to be screened with gFOB every 2 years between the ages of 50 and 74 [119]. The European Commission in 2022 recommended annual FIT as a first-line test for people aged 50-74, with colonoscopy referrals exclusively for those with positive stool testing [120]. Asian countries such as South Korea recommend using colonoscopy, gFOB, or FIT for CRC screening. Chinese recommendations include gFOB or FIT every 3 years, Saudi Arabia guidelines encourage colonoscopy every 10 years [112,121].
One study aimed to identify ways EO-CRC could be diagnosed earlier in those aged 40 to 49 years. Gupta et al. found that roughly one quarter of all individuals diagnosed with EO-CRC in this age group met criteria for early screening due to family history. Another population-based study was designed to determine what proportion of EO-CRC cases could have been prevented if current screening guidelines were followed. The findings of this study suggested that if current screening guidelines were upheld, 52% of EO-CRC cases could have been identified sooner and 16% could have potentially been prevented [122]. Hence, using proper screening strategies could help with prevention or sooner detection of EO-CRC in select populations [122]. Having a first degree relative with colorectal cancer confers a 2-times greater likelihood for developing this disease. Therefore, the US Multisociaty Task Force on CRC (USMSRF) recommends that high risk populations commence screening through colonoscopy by age 40 at the latest. Screening can start earlier if needed, and is recommended for 10 years prior to the age of diagnosis in the first degree relative if this would lead to screening before age 40 [123].
Patients who carry hereditary CRC syndromes are recommended to begin screening for CRC even earlier. Individuals with FAP are recommended to begin screening at the age of 10-12, those affected by Lynch Syndrome are recommended to begin screening at the age of 20-25, and patients with biallelic MUTYH-associated polyposis are recommended to begin screening at the age of 25-30 [124,125,126]. Lastly, individuals with either Juvenile polyposis or Peutz–Jeghers are recommended to initiate screening at 15 years [124].

7. Conclusion

Colorectal, gastric, pancreatic, and biliary tract malignancies have seen a rise in incidence amongst young adults over the past thirty years [127]. Early screening for high-risk populations, such as those with an established family history and/or genetic predisposition, can aid in cancer prevention and decrease the morbidity of cancer through earlier detection and treatment [123]. Individuals with obesity, Crohns or ulcerative colitis, a sedentary lifestyle, diabetes, a history of tobacco use, and with unhealthy dietary habits are of particular risk for CRC [128]. Alcohol and smoking are well-established risk factors for EOPC and PSC places individuals at a high risk for biliary malignancy [65,89,91]. CDH1 abnormalities and PJS are known genetic risk factors for early-onset gastric cancer [35,37]. Lifestyle factors, such as obesity or morbid obesity, dramatically increase the risk of early-onset esophageal adenocarcinoma. Although there are many established genetic and environmental susceptibilities for early onset gastrointestinal carcinogenesis, future population-based studies may help identify additional risk factors to permit further tailoring of cancer prevention and early detection strategies.

Author Contributions

AV and SK performed majority of the literature search and writing. APM, PAH, and SGK provided input in the writing process and performed critical revision of the final manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Conflicts of Interest

Krishna SG – research grant support (investigator-initiated studies) from Mauna Kea Technologies, Paris, France, and Taewoong Medical, USA.

References

  1. Ugai, T.; Sasamoto, N.; Lee, H.-Y.; Ando, M.; Song, M.; Tamimi, R.M.; Kawachi, I.; Campbell, P.T.; Giovannucci, E.L.; Weiderpass, E. Is early-onset cancer an emerging global epidemic? Current evidence and future implications. Nature Reviews Clinical Oncology 2022, 19, 656–673. [Google Scholar] [CrossRef]
  2. Park, J.H.; Hong, J.Y.; Shen, J.J.; Han, K.; Park, J.O.; Park, Y.S.; Lim, H.Y. Increased Risk of Young-Onset Digestive Tract Cancers Among Young Adults Age 20-39 Years With Nonalcoholic Fatty Liver Disease: A Nationwide Cohort Study. J Clin Oncol 2023, 41, 3363–3373. [Google Scholar] [CrossRef]
  3. Koh, B.; Tan, D.J.H.; Ng, C.H.; Fu, C.E.; Lim, W.H.; Zeng, R.W.; Yong, J.N.; Koh, J.H.; Syn, N.; Meng, W. Patterns in Cancer Incidence Among People Younger Than 50 Years in the US, 2010 to 2019. JAMA Network Open 2023, 6, e2328171–e2328171. [Google Scholar] [CrossRef]
  4. Morgan, E.; Soerjomataram, I.; Rumgay, H.; Coleman, H.G.; Thrift, A.P.; Vignat, J.; Laversanne, M.; Ferlay, J.; Arnold, M. The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: new estimates from GLOBOCAN 2020. Gastroenterology 2022, 163, 649–658. [Google Scholar] [CrossRef] [PubMed]
  5. Xie, S.-H.; Rabbani, S.; Petrick, J.L.; Cook, M.B.; Lagergren, J. Racial and Ethnic Disparities in the Incidence of Esophageal Cancer in the United States, 1992–2013. American Journal of Epidemiology 2017, 186, 1341–1351. [Google Scholar] [CrossRef] [PubMed]
  6. Stephanie, M.; Nour, H.; de Sá Inês, M.; Shanker, K.; Kevin, K.; Mario, D.-R.; Prateek, S. Gender differences in Barrett’s esophagus and progression of disease: a systematic review and meta-analysis. Diseases of the Esophagus 2022, 35, doab075. [Google Scholar] [CrossRef] [PubMed]
  7. Codipilly, D.C.; Sawas, T.; Dhaliwal, L.; Johnson, M.L.; Lansing, R.; Wang, K.K.; Leggett, C.L.; Katzka, D.A.; Iyer, P.G. Epidemiology and outcomes of young-onset esophageal adenocarcinoma: an analysis from a population-based database. Cancer Epidemiology, Biomarkers & Prevention 2021, 30, 142–149. [Google Scholar]
  8. Schell, D.; Ullah, S.; Brooke-Smith, M.E.; Hollington, P.; Yeow, M.; Karapetis, C.S.; Watson, D.I.; Pandol, S.J.; Roberts, C.T.; Barreto, S.G. Gastrointestinal adenocarcinoma incidence and survival trends in South Australia, 1990–2017. Cancers 2022, 14, 275. [Google Scholar] [CrossRef] [PubMed]
  9. Torrejon, N.V.; Deshpande, S.; Wei, W.; Tullio, K.; Kamath, S.D. Proportion of early-onset gastric and esophagus cancers has changed over time with disproportionate impact on Black and Hispanic patients. JCO Oncology Practice 2022, 18, e759–e769. [Google Scholar] [CrossRef] [PubMed]
  10. Liu, K.S.; Raza, S.A.; El-Serag, H.B.; Thrift, A.P. Trends in Esophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma Incidence in the United States from 1992 to 2019. Cancers 2022, 14, 6049. [Google Scholar] [CrossRef]
  11. Hussan, H.; Patel, A.; Le Roux, M.; Cruz-Monserrate, Z.; Porter, K.; Clinton, S.K.; Carethers, J.M.; Courneya, K.S. Rising Incidence of Colorectal Cancer in Young Adults Corresponds With Increasing Surgical Resections in Obese Patients. Clin Transl Gastroenterol 2020, 11, e00160. [Google Scholar] [CrossRef] [PubMed]
  12. Allemani, C.; Matsuda, T.; Di Carlo, V.; Harewood, R.; Matz, M.; Nikšić, M.; Bonaventure, A.; Valkov, M.; Johnson, C.J.; Estève, J.; et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 2018, 391, 1023–1075. [Google Scholar] [CrossRef] [PubMed]
  13. Morgan, E.; Soerjomataram, I.; Gavin, A.T.; Rutherford, M.J.; Gatenby, P.; Bardot, A.; Ferlay, J.; Bucher, O.; De, P.; Engholm, G.; et al. International trends in oesophageal cancer survival by histological subtype between 1995 and 2014. Gut 2021, 70, 234–242. [Google Scholar] [CrossRef] [PubMed]
  14. Buckle, G.C.; Mmbaga, E.J.; Paciorek, A.; Akoko, L.; Deardorff, K.; Mgisha, W.; Mushi, B.P.; Mwaiselage, J.; Hiatt, R.A.; Zhang, L.; Van Loon, K. Risk Factors Associated With Early-Onset Esophageal Cancer in Tanzania. JCO Glob Oncol 2022, 8, e2100256. [Google Scholar] [CrossRef] [PubMed]
  15. Juo, Y.-Y.; Gibbons, M.A.M.; Dutson, E.; Lin, A.Y.; Yanagawa, J.; Hines, O.J.; Eibl, G.; Chen, Y. Obesity is associated with early onset of gastrointestinal cancers in California. Journal of obesity 2018, 2018. [Google Scholar] [CrossRef] [PubMed]
  16. Wu, I.-C.; Zhao, Y.; Zhai, R.; Liu, G.; Ter-Minassian, M.; Asomaning, K.; Su, L.; Liu, C.-y.; Chen, F.; Kulke, M.H. Association between polymorphisms in cancer-related genes and early onset of esophageal adenocarcinoma. Neoplasia 2011, 13, 386–IN326. [Google Scholar] [CrossRef] [PubMed]
  17. van Nistelrooij, A.M.; van Marion, R.; Biermann, K.; Spaander, M.C.; van Lanschot, J.J.B.; Wijnhoven, B.P.; Dinjens, W.N. Early onset esophageal adenocarcinoma: a distinct molecular entity? Oncoscience 2016, 3, 42. [Google Scholar] [CrossRef] [PubMed]
  18. Shaheen, N.J.; Falk, G.W.; Iyer, P.G.; Souza, R.F.; Yadlapati, R.H.; Sauer, B.G.; Wani, S. Diagnosis and management of Barrett’s esophagus: an updated ACG guideline. The American journal of gastroenterology 2022, 117, 559. [Google Scholar] [CrossRef]
  19. Wong, M.C.; Deng, Y.; Huang, J.; Bai, Y.; Wang, H.H.; Yuan, J.; Zhang, L.; Yip, H.C.; Chiu, P.W.Y. Performance of screening tests for esophageal squamous cell carcinoma: a systematic review and meta-analysis. Gastrointestinal Endoscopy 2022, 96, 197–207. e134. [Google Scholar] [CrossRef]
  20. Saeian, K.; Staff, D.M.; Vasilopoulos, S.; Townsend, W.F.; Almagro, U.A.; Komorowski, R.A.; Choi, H.; Shaker, R. Unsedated transnasal endoscopy accurately detects Barrett’s metaplasia and dysplasia. Gastrointestinal endoscopy 2002, 56, 472–478. [Google Scholar] [CrossRef]
  21. Benaglia, T.; Sharples, L.D.; Fitzgerald, R.C.; Lyratzopoulos, G. Health benefits and cost effectiveness of endoscopic and nonendoscopic cytosponge screening for Barrett’s esophagus. Gastroenterology 2013, 144, 62–73. e66. [Google Scholar] [CrossRef] [PubMed]
  22. Freeman, M.; Offman, J.; Walter, F.M.; Sasieni, P.; Smith, S.G. Acceptability of the Cytosponge procedure for detecting Barrett’s oesophagus: a qualitative study. BMJ open 2017, 7, e013901. [Google Scholar] [CrossRef] [PubMed]
  23. Dong, E.; Duan, L.; Wu, B.U. Racial and ethnic minorities at increased risk for gastric cancer in a regional US population study. Clinical Gastroenterology and Hepatology 2017, 15, 511–517. [Google Scholar] [CrossRef] [PubMed]
  24. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians 2021, 71, 209–249. [Google Scholar] [CrossRef] [PubMed]
  25. Colquhoun, A.; Arnold, M.; Ferlay, J.; Goodman, K.; Forman, D.; Soerjomataram, I. Global patterns of cardia and non-cardia gastric cancer incidence in 2012. Gut 2015, 64, 1881–1888. [Google Scholar] [CrossRef]
  26. Morgan, E.; Arnold, M.; Camargo, M.C.; Gini, A.; Kunzmann, A.T.; Matsuda, T.; Meheus, F.; Verhoeven, R.H.; Vignat, J.; Laversanne, M. The current and future incidence and mortality of gastric cancer in 185 countries, 2020–40: A population-based modelling study. EClinicalMedicine 2022, 47, 101404. [Google Scholar] [CrossRef]
  27. Bergquist, J.R.; Leiting, J.L.; Habermann, E.B.; Cleary, S.P.; Kendrick, M.L.; Smoot, R.L.; Nagorney, D.M.; Truty, M.J.; Grotz, T.E. Early-onset gastric cancer is a distinct disease with worrisome trends and oncogenic features. Surgery 2019, 166, 547–555. [Google Scholar] [CrossRef]
  28. Wong, M.C.; Huang, J.; Chan, P.S.; Choi, P.; Lao, X.Q.; Chan, S.M.; Teoh, A.; Liang, P. Global incidence and mortality of gastric cancer, 1980-2018. JAMA network open 2021, 4, e2118457–e2118457. [Google Scholar] [CrossRef] [PubMed]
  29. He, Y.; Wang, Y.; Luan, F.; Yu, Z.; Feng, H.; Chen, B.; Chen, W. Chinese and global burdens of gastric cancer from 1990 to 2019. Cancer Medicine 2021, 10, 3461–3473. [Google Scholar] [CrossRef] [PubMed]
  30. Correa, P.; Shiao, Y.-h. Phenotypic and genotypic events in gastric carcinogenesis. Cancer research 1994, 54, 1941s–1943s. [Google Scholar]
  31. Milne, A.N.; Sitarz, R.; Carvalho, R.; Carneiro, F.; A Offerhaus, G.J. Early onset gastric cancer: on the road to unraveling gastric carcinogenesis. Current molecular medicine 2007, 7, 15–28. [Google Scholar] [CrossRef] [PubMed]
  32. Setia, N.; Wang, C.X.; Lager, A.; Maron, S.; Shroff, S.; Arndt, N.; Peterson, B.; Kupfer, S.S.; Ma, C.; Misdraji, J. Morphologic and molecular analysis of early-onset gastric cancer. Cancer 2021, 127, 103–114. [Google Scholar] [CrossRef] [PubMed]
  33. Figueiredo, J.; Melo, S.; Carneiro, P.; Moreira, A.M.; Fernandes, M.S.; Ribeiro, A.S.; Guilford, P.; Paredes, J.; Seruca, R. Clinical spectrum and pleiotropic nature of CDH1 germline mutations. Journal of Medical Genetics 2019, 56, 199–208. [Google Scholar] [CrossRef] [PubMed]
  34. Carneiro, F.; Oliveira, C.; Suriano, G.; Seruca, R. Molecular pathology of familial gastric cancer, with an emphasis on hereditary diffuse gastric cancer. Journal of clinical pathology 2008, 61, 25–30. [Google Scholar] [CrossRef] [PubMed]
  35. Bacani, J.T.; Soares, M.; Zwingerman, R.; Di Nicola, N.; Senz, J.; Riddell, R.; Huntsman, D.G.; Gallinger, S. CDH1/E-cadherin germline mutations in early-onset gastric cancer. Journal of medical genetics 2006, 43, 867–872. [Google Scholar] [CrossRef] [PubMed]
  36. Bar-Mashiah, A.; Ahsan, M.D.; McGonigle, R.; Sharaf, R.N. Risk of gastric cancer and utility of endoscopic screening for lynch syndrome patients. Foregut 2023, 3, 60–68. [Google Scholar] [CrossRef]
  37. Takahashi, M.; Sakayori, M.; Takahashi, S.; Kato, T.; Kaji, M.; Kawahara, M.; Suzuki, T.; Kato, S.; Kato, S.; Shibata, H. A novel germline mutation of the LKB1 gene in a patient with Peutz-Jeghers syndrome with early-onset gastric cancer. Journal of gastroenterology 2004, 39, 1210–1214. [Google Scholar] [CrossRef]
  38. Ishida, H.; Ishibashi, K.; Iwama, T. Malignant tumors associated with juvenile polyposis syndrome in Japan. Surgery Today 2018, 48, 253–263. [Google Scholar] [CrossRef]
  39. Rugge, M.; Busatto, G.; Cassaro, M.; Shiao, Y.H.; Russo, V.; Leandro, G.; Avellini, C.; Fabiano, A.; Sidoni, A.; Covacci, A. Patients younger than 40 years with gastric carcinoma: Helicobacter pylori genotype and associated gastritis phenotype. Cancer 1999, 85, 2506–2511. [Google Scholar] [CrossRef]
  40. Huang, J.Q.; Zheng, G.F.; Sumanac, K.; Irvine, E.J.; Hunt, R.H. Meta-analysis of the relationship between cagA seropositivity and gastric cancer. Gastroenterology 2003, 125, 1636–1644. [Google Scholar] [CrossRef]
  41. Webb, P.; Law, M.; Varghese, C.; Forman, D.; Yuan, J.; Yu, M.; Ross, R.; Limberg, P.; Mark, S.; Taylor, P.; Helicobacter Canc Collaborative G. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 2001, 49, 347–353. [Google Scholar]
  42. Kuipers, E.; Klinkenberg-Knol, E.; Vandenbroucke-Grauls, C.; Appelmelk, B.; Schenk, B.; Meuwissen, S. Role of Helicobacter pylori in the pathogenesis of atrophic gastritis. Scandinavian journal of gastroenterology. Supplement 1997, 223, 28–34. [Google Scholar]
  43. Sipponen, P.; Marshall, B.J. Gastritis and gastric cancer: Western countries. Gastroenterology clinics of north America 2000, 29, 579–592. [Google Scholar] [CrossRef] [PubMed]
  44. Kato, I.; Tominaga, S.; Ito, Y.; Kobayashi, S.; Yoshii, Y.; Matsuura, A.; Kameya, A.; Kano, T.; Ikari, A. A prospective study of atrophic gastritis and stomach cancer risk. Japanese journal of cancer research 1992, 83, 1137–1142. [Google Scholar] [CrossRef]
  45. Liu, H.; Li, Z.; Zhang, Q.; Li, Q.; Zhong, H.; Wang, Y.; Yang, H.; Li, H.; Wang, X.; Li, K. Multi-institutional development and validation of a nomogram to predict prognosis of early-onset gastric cancer patients. Frontiers in Immunology 2022, 13, 1007176. [Google Scholar] [CrossRef] [PubMed]
  46. Giryes, A.; Oweira, H.; Mannhart, M.; Decker, M.; Abdel-Rahman, O. Exploring the differences between early-onset gastric cancer and traditional-onset gastric cancer. Journal of Gastrointestinal Oncology 2018, 9, 1157. [Google Scholar] [CrossRef] [PubMed]
  47. Kim, G.H.; Liang, P.S.; Bang, S.J.; Hwang, J.H. Screening and surveillance for gastric cancer in the United States: Is it needed? Gastrointestinal endoscopy 2016, 84, 18–28. [Google Scholar] [CrossRef] [PubMed]
  48. Kim, G.H.; Bang, S.J.; Ende, A.R.; Hwang, J.H. Is screening and surveillance for early detection of gastric cancer needed in Korean Americans? The Korean Journal of Internal Medicine 2015, 30, 747. [Google Scholar] [CrossRef] [PubMed]
  49. Syngal, S.; Brand, R.E.; Church, J.M.; Giardiello, F.M.; Hampel, H.L.; Burt, R.W. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol 2015, 110, 223–262; quiz 263. [Google Scholar] [CrossRef]
  50. Yashima, K.; Shabana, M.; Kurumi, H.; Kawaguchi, K.; Isomoto, H. Gastric cancer screening in Japan: a narrative review. Journal of clinical medicine 2022, 11, 4337. [Google Scholar] [CrossRef]
  51. Hamashima, C. Cancer screening guidelines and policy making: 15 years of experience in cancer screening guideline development in Japan. Japanese Journal of Clinical Oncology 2018, 48, 278–286. [Google Scholar] [CrossRef]
  52. Leung, C.; Huang, H.; Saito, E.; Nomura, S.; Katanoda, K.; Matsuda, T.; Shibuya, K. Benefits and harms of gastric cancer screening and prevention in Japan: a microsimulation modeling analysis. 2018. [Google Scholar] [CrossRef]
  53. Arbuthnot, P.; Kew, M. Hepatitis B virus and hepatocellular carcinoma. Int J Exp Pathol 2001, 82, 77–100. [Google Scholar] [CrossRef] [PubMed]
  54. Dasgupta, P.; Henshaw, C.; Youlden, D.R.; Clark, P.J.; Aitken, J.F.; Baade, P.D. Global trends in incidence rates of primary adult liver cancers: a systematic review and meta-analysis. Frontiers in oncology 2020, 10, 171. [Google Scholar] [CrossRef] [PubMed]
  55. Islami, F.; Miller, K.D.; Siegel, R.L.; Fedewa, S.A.; Ward, E.M.; Jemal, A. Disparities in liver cancer occurrence in the United States by race/ethnicity and state. CA: a cancer journal for clinicians 2017, 67, 273–289. [Google Scholar] [CrossRef] [PubMed]
  56. Thylur, R.P.; Roy, S.K.; Shrivastava, A.; LaVeist, T.A.; Shankar, S.; Srivastava, R.K. Assessment of risk factors, and racial and ethnic differences in hepatocellular carcinoma. JGH Open 2020, 4, 351–359. [Google Scholar] [CrossRef] [PubMed]
  57. Antwi, S.O.; Mousa, O.Y.; Patel, T. Racial, ethnic, and age disparities in incidence and survival of intrahepatic cholangiocarcinoma in the United States; 1995-2014. Annals of hepatology 2018, 17, 274–285. [Google Scholar] [CrossRef] [PubMed]
  58. Rich, N.E.; Yopp, A.C.; Singal, A.G.; Murphy, C.C. Hepatocellular carcinoma incidence is decreasing among younger adults in the United States. Clinical Gastroenterology and Hepatology 2020, 18, 242–248. e245. [Google Scholar] [CrossRef] [PubMed]
  59. Van Dyke, A.L.; Shiels, M.S.; Jones, G.S.; Pfeiffer, R.M.; Petrick, J.L.; Beebe-Dimmer, J.L.; Koshiol, J. Biliary tract cancer incidence and trends in the United States by demographic group, 1999-2013. Cancer 2019, 125, 1489–1498. [Google Scholar] [CrossRef]
  60. Park, C.H.; Jeong, S.H.; Yim, H.W.; Kim, J.D.; Bae, S.H.; Choi, J.Y.; Yoon, S.K. Family history influences the early onset of hepatocellular carcinoma. World J Gastroenterol 2012, 18, 2661–2667. [Google Scholar] [CrossRef]
  61. Li, Y.; Zhang, Z.; Shi, J.; Jin, L.; Wang, L.; Xu, D.; Wang, F.S. Risk factors for naturally-occurring early-onset hepatocellular carcinoma in patients with HBV-associated liver cirrhosis in China. Int J Clin Exp Med 2015, 8, 1205–1212. [Google Scholar]
  62. Wan, D.W.; Tzimas, D.; Smith, J.A.; Kim, S.; Araujo, J.; David, R.; Lobach, I.; Sarpel, U. Risk factors for early-onset and late-onset hepatocellular carcinoma in Asian immigrants with hepatitis B in the United States. Am J Gastroenterol 2011, 106, 1994–2000. [Google Scholar] [CrossRef] [PubMed]
  63. Lam, C.M.; Chan, A.O.; Ho, P.; Ng, I.O.; Lo, C.M.; Liu, C.L.; Poon, R.T.; Fan, S.T. Different presentation of hepatitis B-related hepatocellular carcinoma in a cohort of 1863 young and old patients - implications for screening. Aliment Pharmacol Ther 2004, 19, 771–777. [Google Scholar] [CrossRef]
  64. Taylor, A.C.F.; Palmer, K.R. Caroli’s disease. European Journal of Gastroenterology & Hepatology 1998, 10, 105–108. [Google Scholar]
  65. Tyson, G.L.; El-Serag, H.B. Risk factors for cholangiocarcinoma. Hepatology 2011, 54, 173–184. [Google Scholar] [CrossRef] [PubMed]
  66. Aune, D.; Sen, A.; Norat, T.; Riboli, E.; Folseraas, T. Primary sclerosing cholangitis and the risk of cancer, cardiovascular disease, and all-cause mortality: a systematic review and meta-analysis of cohort studies. Scientific Reports 2021, 11, 10646. [Google Scholar] [CrossRef] [PubMed]
  67. Molodecky, N.A.; Kareemi, H.; Parab, R.; Barkema, H.W.; Quan, H.; Myers, R.P.; Kaplan, G.G. Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis. Hepatology 2011, 53, 1590–1599. [Google Scholar] [CrossRef] [PubMed]
  68. Marrero, J.A.; Kulik, L.M.; Sirlin, C.B.; Zhu, A.X.; Finn, R.S.; Abecassis, M.M.; Roberts, L.R.; Heimbach, J.K. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2018, 68, 723–750. [Google Scholar] [CrossRef] [PubMed]
  69. Heimbach, J.K.; Kulik, L.M.; Finn, R.S.; Sirlin, C.B.; Abecassis, M.M.; Roberts, L.R.; Zhu, A.X.; Murad, M.H.; Marrero, J.A. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018, 67, 358–380. [Google Scholar] [CrossRef]
  70. Charatcharoenwitthaya, P.; Enders, F.B.; Halling, K.C.; Lindor, K.D. Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology 2008, 48, 1106–1117. [Google Scholar] [CrossRef]
  71. Khuntikeo, N.; Koonmee, S.; Sa-Ngiamwibool, P.; Chamadol, N.; Laopaiboon, V.; Titapun, A.; Yongvanit, P.; Loilome, W.; Namwat, N.; Andrews, R.H.; et al. A comparison of the proportion of early stage cholangiocarcinoma found in an ultrasound-screening program compared to walk-in patients. HPB (Oxford) 2020, 22, 874–883. [Google Scholar] [CrossRef]
  72. Khuntikeo, N.; Chamadol, N.; Yongvanit, P.; Loilome, W.; Namwat, N.; Sithithaworn, P.; Andrews, R.H.; Petney, T.N.; Promthet, S.; Thinkhamrop, K.; et al. Cohort profile: cholangiocarcinoma screening and care program (CASCAP). BMC Cancer 2015, 15, 459. [Google Scholar] [CrossRef] [PubMed]
  73. Garcia, P.L.; Miller, A.L.; Yoon, K.J. Patient-derived xenograft models of pancreatic cancer: overview and comparison with other types of models. Cancers 2020, 12, 1327. [Google Scholar] [CrossRef] [PubMed]
  74. Bardeesy, N.; DePinho, R.A. Pancreatic cancer biology and genetics. Nature Reviews Cancer 2002, 2, 897–909. [Google Scholar] [CrossRef] [PubMed]
  75. Lippi, G.; Mattiuzzi, C. The global burden of pancreatic cancer. Archives of Medical Science 2020, 16. [Google Scholar] [CrossRef] [PubMed]
  76. Arnold, M.; Abnet, C.C.; Neale, R.E.; Vignat, J.; Giovannucci, E.L.; McGlynn, K.A.; Bray, F. Global burden of 5 major types of gastrointestinal cancer. Gastroenterology 2020, 159, 335–349. e315. [Google Scholar] [CrossRef] [PubMed]
  77. Pijnappel, E.N.; Schuurman, M.; Wagner, A.D.; de Vos-Geelen, J.; van der Geest, L.G.; de Groot, J.-W.B.; Koerkamp, B.G.; de Hingh, I.H.; Homs, M.Y.; Creemers, G.-J. Sex, gender and age differences in treatment allocation and survival of patients with metastatic pancreatic cancer: a nationwide study. Frontiers in oncology 2022, 12, 839779. [Google Scholar] [CrossRef]
  78. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2020. CA Cancer J Clin 2020, 70, 7–30. [Google Scholar] [CrossRef]
  79. Rahib, L.; Smith, B.D.; Aizenberg, R.; Rosenzweig, A.B.; Fleshman, J.M.; Matrisian, L.M. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer research 2014, 74, 2913–2921. [Google Scholar] [CrossRef]
  80. Tavakkoli, A.; Singal, A.G.; Waljee, A.K.; Elmunzer, B.J.; Pruitt, S.L.; McKey, T.; Rubenstein, J.H.; Scheiman, J.M.; Murphy, C.C. Racial disparities and trends in pancreatic cancer incidence and mortality in the United States. Clinical Gastroenterology and Hepatology 2020, 18, 171–178. [Google Scholar] [CrossRef]
  81. Sung, H.; Siegel, R.L.; Rosenberg, P.S.; Jemal, A. Emerging cancer trends among young adults in the USA: analysis of a population-based cancer registry. The Lancet Public Health 2019, 4, e137–e147. [Google Scholar] [CrossRef]
  82. Ramai, D.; Facciorusso, A.; Hart, P.A.; Barakat, M.T. Rising Incidence of Pancreatic Cancer in Patients 20 to 39 Years: A Population-Based Observational Study. Pancreas 2023, 52, e213–e215. [Google Scholar] [CrossRef]
  83. LaPelusa, M.; Shen, C.; Arhin, N.D.; Cardin, D.; Tan, M.; Idrees, K.; Geevarghese, S.; Chakravarthy, B.; Berlin, J.; Eng, C. Trends in the incidence and treatment of early-onset pancreatic cancer. Cancers 2022, 14, 283. [Google Scholar] [CrossRef]
  84. Khalaf, N.; El-Serag, H.B.; Abrams, H.R.; Thrift, A.P. Burden of pancreatic cancer: from epidemiology to practice. Clinical Gastroenterology and Hepatology 2021, 19, 876–884. [Google Scholar] [CrossRef]
  85. Siegel, R.L.; Giaquinto, A.N.; Jemal, A. Cancer statistics, 2024. CA: A Cancer Journal for Clinicians 2024, 74, 12–49. [Google Scholar] [CrossRef] [PubMed]
  86. Ren, S.; Sadula, A.; Ye, C.; Chen, Q.; Yuan, M.; Meng, M.; Lei, J.; Li, G.; Yuan, C. Clinical characteristics, treatment patterns and survival outcomes of early-onset pancreatic adenocarcinoma: a population-based study. Am J Transl Res 2023, 15, 407–421. [Google Scholar] [PubMed]
  87. Diaz, K.E.; Lucas, A.L. Familial pancreatic ductal adenocarcinoma. The American Journal of Pathology 2019, 189, 36–43. [Google Scholar] [CrossRef]
  88. James, T.A.; Sheldon, D.G.; Rajput, A.; Kuvshinoff, B.W.; Javle, M.M.; Nava, H.R.; Smith, J.L.; Gibbs, J.F. Risk factors associated with earlier age of onset in familial pancreatic carcinoma. Cancer: Interdisciplinary International Journal of the American Cancer Society 2004, 101, 2722–2726. [Google Scholar] [CrossRef] [PubMed]
  89. McWilliams, R.R.; Maisonneuve, P.; Bamlet, W.R.; Petersen, G.M.; Li, D.; Risch, H.; Yu, H.; Fontham, E.T.; Luckett, B.; Bosetti, C. Risk factors for early-onset and very-early-onset pancreatic adenocarcinoma: a pancreatic cancer case-control consortium (PanC4) analysis. Pancreas 2016, 45, 311. [Google Scholar] [CrossRef]
  90. Bannon, S.A.; Montiel, M.F.; Goldstein, J.B.; Dong, W.; Mork, M.E.; Borras, E.; Hasanov, M.; Varadhachary, G.R.; Maitra, A.; Katz, M.H. High prevalence of hereditary cancer syndromes and outcomes in adults with early-onset pancreatic cancer. Cancer Prevention Research 2018, 11, 679–686. [Google Scholar] [CrossRef]
  91. Piciucchi, M.; Capurso, G.; Valente, R.; Larghi, A.; Archibugi, L.; Signoretti, M.; Stigliano, S.; Zerboni, G.; Barucca, V.; La Torre, M. Early onset pancreatic cancer: risk factors, presentation and outcome. Pancreatology 2015, 15, 151–155. [Google Scholar] [CrossRef]
  92. Goggins, M.; Overbeek, K.A.; Brand, R.; Syngal, S.; Del Chiaro, M.; Bartsch, D.K.; Bassi, C.; Carrato, A.; Farrell, J.; Fishman, E.K.; et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut 2020, 69, 7–17. [Google Scholar] [CrossRef]
  93. National Comprehensive Cancer Network. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. In Clinical Practice Guidelines in Oncology Version 1.2022; 2022. [Google Scholar]
  94. Haupt, B.; Ro, J.Y.; Schwartz, M.R.; Shen, S.S. Colorectal adenocarcinoma with micropapillary pattern and its association with lymph node metastasis. Modern Pathology 2007, 20, 729–733. [Google Scholar] [CrossRef]
  95. Siegel, R.L.; Wagle, N.S.; Cercek, A.; Smith, R.A.; Jemal, A. Colorectal cancer statistics, 2023. CA: a cancer journal for clinicians 2023, 73, 233–254. [Google Scholar] [CrossRef]
  96. Morgan, E.; Arnold, M.; Gini, A.; Lorenzoni, V.; Cabasag, C.; Laversanne, M.; Vignat, J.; Ferlay, J.; Murphy, N.; Bray, F. Global burden of colorectal cancer in 2020 and 2040: Incidence and mortality estimates from GLOBOCAN. Gut 2023, 72, 338–344. [Google Scholar] [CrossRef] [PubMed]
  97. Demb, J.; Gupta, S. Racial and Ethnic Disparities in Colorectal Cancer Screening Pose Persistent Challenges to Health Equity. Clin Gastroenterol Hepatol 2020, 18, 1691–1693. [Google Scholar] [CrossRef] [PubMed]
  98. DeSantis, C.E.; Miller, K.D.; Goding Sauer, A.; Jemal, A.; Siegel, R.L. Cancer statistics for african americans, 2019. CA: a cancer journal for clinicians 2019, 69, 211–233. [Google Scholar] [CrossRef] [PubMed]
  99. Sineshaw, H.M.; Robbins, A.S.; Jemal, A. Disparities in survival improvement for metastatic colorectal cancer by race/ethnicity and age in the United States. Cancer causes & control 2014, 25, 419–423. [Google Scholar]
  100. Tanaka, L.F.; Figueroa, S.H.; Popova, V.; Klug, S.J.; Buttmann-Schweiger, N. The Rising Incidence of Early-Onset Colorectal Cancer. Dtsch Arztebl Int 2023, 120, 59–64. [Google Scholar] [CrossRef]
  101. Bailey, C.E.; Hu, C.Y.; You, Y.N.; Bednarski, B.K.; Rodriguez-Bigas, M.A.; Skibber, J.M.; Cantor, S.B.; Chang, G.J. Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010. JAMA Surg 2015, 150, 17–22. [Google Scholar] [CrossRef]
  102. Feletto, E.; Yu, X.Q.; Lew, J.-B.; St John, D.J.B.; Jenkins, M.A.; Macrae, F.A.; Mahady, S.E.; Canfell, K. Trends in colon and rectal cancer incidence in Australia from 1982 to 2014: analysis of data on over 375,000 cases. Cancer Epidemiology, Biomarkers & Prevention 2019, 28, 83–90. [Google Scholar]
  103. Siegel, R.L.; Torre, L.A.; Soerjomataram, I.; Hayes, R.B.; Bray, F.; Weber, T.K.; Jemal, A. Global patterns and trends in colorectal cancer incidence in young adults. Gut 2019, 68, 2179–2185. [Google Scholar] [CrossRef] [PubMed]
  104. Brenner, D.R.; Ruan, Y.; Shaw, E.; De, P.; Heitman, S.J.; Hilsden, R.J. Increasing colorectal cancer incidence trends among younger adults in Canada. Preventive medicine 2017, 105, 345–349. [Google Scholar] [CrossRef]
  105. Archambault, A.N.; Lin, Y.; Jeon, J.; Harrison, T.A.; Bishop, D.T.; Brenner, H.; Casey, G.; Chan, A.T.; Chang-Claude, J.; Figueiredo, J.C. Nongenetic determinants of risk for early-onset colorectal cancer. JNCI cancer spectrum 2021, 5, pkab029. [Google Scholar] [CrossRef] [PubMed]
  106. Chang, V.C.; Cotterchio, M.; De, P.; Tinmouth, J. Risk factors for early-onset colorectal cancer: a population-based case–control study in Ontario, Canada. Cancer causes & control 2021, 32, 1063–1083. [Google Scholar]
  107. Pearlman, R.; Frankel, W.L.; Swanson, B.; Zhao, W.; Yilmaz, A.; Miller, K.; Bacher, J.; Bigley, C.; Nelsen, L.; Goodfellow, P.J.; et al. Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer. JAMA Oncol 2017, 3, 464–471. [Google Scholar] [CrossRef]
  108. Stoffel, E.M.; Koeppe, E.; Everett, J.; Ulintz, P.; Kiel, M.; Osborne, J.; Williams, L.; Hanson, K.; Gruber, S.B.; Rozek, L.S. Germline genetic features of young individuals with colorectal cancer. Gastroenterology 2018, 154, 897–905. e891. [Google Scholar] [CrossRef]
  109. de Voer, R.M.; Hahn, M.-M.; Weren, R.D.; Mensenkamp, A.R.; Gilissen, C.; van Zelst-Stams, W.A.; Spruijt, L.; Kets, C.M.; Zhang, J.; Venselaar, H. Identification of novel candidate genes for early-onset colorectal cancer susceptibility. PLoS genetics 2016, 12, e1005880. [Google Scholar] [CrossRef] [PubMed]
  110. Mork, M.E.; You, Y.N.; Ying, J.; Bannon, S.A.; Lynch, P.M.; Rodriguez-Bigas, M.A.; Vilar, E. High Prevalence of Hereditary Cancer Syndromes in Adolescents and Young Adults With Colorectal Cancer. J Clin Oncol 2015, 33, 3544–3549. [Google Scholar] [CrossRef]
  111. Clebak, K.T.; Nickolich, S.; Mendez-Miller, M. Multitarget Stool DNA Testing (Cologuard) for Colorectal Cancer Screening. Am Fam Physician 2022, 105, 198–200. [Google Scholar]
  112. Schreuders, E.H.; Ruco, A.; Rabeneck, L.; Schoen, R.E.; Sung, J.J.; Young, G.P.; Kuipers, E.J. Colorectal cancer screening: a global overview of existing programmes. Gut 2015, 64, 1637–1649. [Google Scholar] [CrossRef]
  113. Ferrari, A.; Neefs, I.; Hoeck, S.; Peeters, M.; Van Hal, G. Towards novel non-invasive colorectal cancer screening methods: a comprehensive review. Cancers 2021, 13, 1820. [Google Scholar] [CrossRef]
  114. Hol, L.; Van Leerdam, M.E.; Van Ballegooijen, M.; Van Vuuren, A.J.; Van Dekken, H.; Reijerink, J.C.; Van der Togt, A.C.; Habbema, J.; Kuipers, E.J. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 2010, 59, 62–68. [Google Scholar] [CrossRef]
  115. Nishihara, R.; Wu, K.; Lochhead, P.; Morikawa, T.; Liao, X.; Qian, Z.R.; Inamura, K.; Kim, S.A.; Kuchiba, A.; Yamauchi, M.; et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med 2013, 369, 1095–1105. [Google Scholar] [CrossRef]
  116. Force, U.P.S.T. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 2021, 325, 1965–1977. [Google Scholar] [CrossRef]
  117. Shirley, M. Epi proColon® for colorectal cancer screening: A profile of its use in the USA. Molecular Diagnosis & Therapy 2020, 24, 497–503. [Google Scholar]
  118. Public Guidelines: Colorectal Cancer (2016). Available online: https://canadiantaskforce.ca/guidelines/published-guidelines/colorectal-cancer/#:~:text=We%20recommend%20screening%20adults%20aged%2050%20to%2059%20for%20CRC,flexible%20sigmoidoscopy%20every%2010%20years.&text=We%20recommend%20not%20screening%20adults%20aged%2075%20years%20and%20over%20for%20CRC.&text=We%20recommend%20not%20using%20colonoscopy%20as%20a%20screening%20test%20for%20CRC. (accessed on February 8).
  119. Jenkins, M.A.; Ait Ouakrim, D.; Boussioutas, A.; Hopper, J.L.; Ee, H.C.; Emery, J.D.; Macrae, F.A.; Chetcuti, A.; Wuellner, L.; St John, D.J.B. Revised Australian national guidelines for colorectal cancer screening: family history. Medical Journal of Australia 2018, 209, 455–460. [Google Scholar] [CrossRef] [PubMed]
  120. European Health Union: Commission welcomes adoption of new EU cancer screening recommendations. Available online: https://ec.europa.eu/commission/presscorner/detail/en/ip_22_7548 (accessed on February 8).
  121. Bénard, F.; Barkun, A.N.; Martel, M.; von Renteln, D. Systematic review of colorectal cancer screening guidelines for average-risk adults: Summarizing the current global recommendations. World J Gastroenterol 2018, 24, 124–138. [Google Scholar] [CrossRef]
  122. Stanich, P.P.; Pelstring, K.R.; Hampel, H.; Pearlman, R. A High Percentage of Early-age Onset Colorectal Cancer Is Potentially Preventable. Gastroenterology 2021, 160, 1850–1852. [Google Scholar] [CrossRef] [PubMed]
  123. Gupta, S.; Bharti, B.; Ahnen, D.J.; Buchanan, D.D.; Cheng, I.C.; Cotterchio, M.; Figueiredo, J.C.; Gallinger, S.J.; Haile, R.W.; Jenkins, M.A. Potential impact of family history–based screening guidelines on the detection of early-onset colorectal cancer. Cancer 2020, 126, 3013–3020. [Google Scholar] [CrossRef]
  124. Kastrinos, F.; Samadder, N.J.; Burt, R.W. Use of Family History and Genetic Testing to Determine Risk of Colorectal Cancer. Gastroenterology 2020, 158, 389–403. [Google Scholar] [CrossRef]
  125. Perrod, G.; Rahmi, G.; Cellier, C. Colorectal cancer screening in Lynch syndrome: Indication, techniques and future perspectives. Dig Endosc 2021, 33, 520–528. [Google Scholar] [CrossRef] [PubMed]
  126. Kyriakidis, F.; Kogias, D.; Venou, T.M.; Karlafti, E.; Paramythiotis, D. Updated Perspectives on the Diagnosis and Management of Familial Adenomatous Polyposis. Appl Clin Genet 2023, 16, 139–153. [Google Scholar] [CrossRef] [PubMed]
  127. Ben-Aharon, I.; van Laarhoven, H.W.M.; Fontana, E.; Obermannova, R.; Nilsson, M.; Lordick, F. Early-Onset Cancer in the Gastrointestinal Tract Is on the Rise-Evidence and Implications. Cancer Discov 2023, 13, 538–551. [Google Scholar] [CrossRef] [PubMed]
  128. Hua, H.; Jiang, Q.; Sun, P.; Xu, X. Risk factors for early-onset colorectal cancer: systematic review and meta-analysis. Front Oncol 2023, 13, 1132306. [Google Scholar] [CrossRef]
Table 1. Overview and characteristics of early onset gastrointestinal and liver cancers.
Table 1. Overview and characteristics of early onset gastrointestinal and liver cancers.
Esophageal cancer Gastric Cancer Pancreatic cancer Colorectal cancer Liver malignancies
Type Esophageal adenocarcinoma (EAC)
Squamous cell carcinoma (SCC)		 Predominantly adenocarcinoma
-Cardia
-Non-cardia		 Predominantly pancreatic ductal adenocarcinoma (PDAC) Predominantly adenocarcinoma Hepatocellular carcinoma (HCC)
Intrahepatic cholangiocarcinoma (ICC)
Global incidence EAC: Increasing
SCC: Decreasing		 Increasing Increasing Increasing HCC: Decreasing
ICC: Increasing
Sex predilection Male > Female Male > Female Male > Female Male > Female Male > Female
Racial predominance EAC: White
SCC: Black 		Black and Hispanic Black Black HCC: AA/PI, Black
ICC: AA/PI
Early onset cancer EAC: Plateau or decreasing
SCC: Decreasing		 Increasing Increasing Increasing
Risks for early onset cancer : Environmental EAC: Barrett’s esophagus, obesity
SCC: Oral hygiene, tobacco smoking		 H. pylori infection
Obesity
Heavy alcohol use		 Heavy alcohol use
Tobacco smoking
Diabetes
Obesity		 Low intake of dietary fiber, folate, and calcium. High intake of alcohol, red meat, and NSAIDs HCC: Chronic hepatitis B infection, tobacco smoking
ICC: Primary sclerosing cholangitis, parasitic infections, hepatolithiasis
Risks for early onset cancer : Genetic, familial Familial Barrett’s esophagus. Family history,
CDH1 germline mutation
Lynch syndrome
Juvenile polyposis syndrome (JPS)
Peutz-Jeghers syndrome (PJS)		 Family history of PDAC.
Multiple germline mutations (BRCA1/2, PALB2, APC ATM, CDKN2A, MLH1, MSH2, MSH6, PMS2, EPCAM STK11, PRSS1)
 Lynch Syndrome
Familial adenomatous polyposis
JPS
PJS
PTEN-hamartoma
HCC: Family history of HCC, family history of Hepatitis B infection
ICC: Congenital disorders of biliary tract
Screening EAC: Barrett’s exophages guidelines
SCC: No specific guidelines		 US: No screening guidelines
East Asia: ≥ 40 years (Korea), ≥ 50 years (Japan)		 PJS ≥ 40 years
CDKN2A ≥40 years
Germline (BRCA2, ATM, PALB2, BRCA1, MLH1/MSH2) ≥45-50 years
Familial PDAC (≥50 or 10 years younger than age of diagnosis of youngest relative)
 Sporadic ≥ 45 (US)
FAP ≥ 10-15 years
Lynch ≥ 20-25 years
JPS and PJS ≥ 15 years
PHTS ≥ 35 years
 HCC: All patients with Cirrhosis
ICC: No specific guidelines
NSAID - Non-steroidal anti-inflammatory drugs; PJS - Peutz-Jeghers syndrome; AA/PI - Asian American/Pacific Islander; CDH1: Cadherin-1 or E-cadherin gene; US: United States.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

facebook logotwitter logolinkedin logo
MDPI Initiatives
Important Links
Subscribe

Disclaimer

Terms of Use

Privacy Policy

© 2024 MDPI (Basel, Switzerland) unless otherwise stated